MacroGenics Announces Annual Meeting of Stockholders on May 21, 2024

TL;DR

<b>MacroGenics will hold its virtual Annual Meeting on May 21, 2024, to elect directors, ratify auditors, approve executive compensation, and amend its equity incentive plan.</b>

AI Summary

MACROGENICS INC (MGNX) filed a Proxy Statement (DEF 14A) with the SEC on April 8, 2024. MacroGenics, Inc. will hold its Annual Meeting of Stockholders on May 21, 2024, virtually. The meeting agenda includes electing three Class II directors, ratifying Ernst & Young LLP as the independent auditor for fiscal year 2024, and approving executive compensation on an advisory basis. Stockholders will also vote on an amendment to the 2023 Equity Incentive Plan to increase available shares by 2,000,000. The record date for stockholders eligible to vote is March 22, 2024. The Board of Directors recommends voting FOR the director nominees and Proposal Nos. 2, 3, and 4.

Why It Matters

For investors and stakeholders tracking MACROGENICS INC, this filing contains several important signals. This filing is a definitive proxy statement, indicating that the company is proceeding with its annual shareholder meeting and seeking votes on key corporate governance and compensation matters. The proposed amendment to the equity incentive plan to increase share availability by 2,000,000 shares is a significant proposal that could impact future dilution and employee compensation strategies.

Risk Assessment

Risk Level: low — MACROGENICS INC shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain new financial results or significant operational updates, thus posing low immediate risk.

Analyst Insight

Stockholders should review the proxy materials to make informed voting decisions on director elections, auditor ratification, executive compensation, and the equity incentive plan amendment.

Key Numbers

• May 21, 2024 — Annual Meeting Date (Date of the Annual Meeting of Stockholders)
• March 22, 2024 — Record Date (Date to determine stockholders eligible to vote)
• 2,000,000 — Additional Shares (Number of shares to be added to the 2023 Equity Incentive Plan)
• 3 — Directors to be Elected (Number of Class II directors to be elected)

Key Players & Entities

• MACROGENICS INC (company) — Registrant
• May 21, 2024 (date) — Annual Meeting date
• Ernst & Young LLP (company) — independent registered public accounting firm
• March 22, 2024 (date) — Record Date for voting eligibility
• 2,000,000 (dollar_amount) — shares to be added to equity incentive plan

FAQ

Industry Context

MacroGenics operates in the pharmaceutical preparations industry, focusing on the development and commercialization of innovative cancer immunotherapies.

Regulatory Implications

The filing is made under Section 14(a) of the Securities Exchange Act of 1934, which governs the solicitation of proxies from shareholders.

What Investors Should Do

1. Review the proxy statement for details on director nominees and their qualifications.
2. Evaluate the proposed amendment to the 2023 Equity Incentive Plan and its potential impact.
3. Consider the company's recommendation for voting on the ratification of Ernst & Young LLP as the independent auditor.

Key Dates

• 2024-05-21: Annual Meeting of Stockholders — To elect directors, ratify auditors, vote on executive compensation, and approve equity plan amendment.
• 2024-03-22: Record Date — Determines eligibility to vote at the Annual Meeting.

Year-Over-Year Comparison

This is a DEF 14A filing for the upcoming annual meeting, distinct from previous filings which would have contained financial results or other operational updates.

Key Financial Figures

• $28,000 — n of proxies for a fee of approximately $28,000 plus the reimbursement of out-of-pocket

Filing Documents

• def_14ax2024.htm (DEF 14A) — 946KB
• imagea.jpg (GRAPHIC) — 7KB
• chart-365ceeebfdf84d18954a.jpg (GRAPHIC) — 125KB
• mgnx_pcxfinalxpagex1a.jpg (GRAPHIC) — 1286KB
• mgnx_pcxfinalxpagex2a.jpg (GRAPHIC) — 527KB
• 0001125345-24-000076.txt (&nbsp;) — 3624KB

Executive Compensation Information

Executive Compensation Information

(v) Pay vs Performance

Item 402(v) Pay vs Performance CEO Pay Ratio Disclosure Information About Equity Compensation Plans

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management Delinquent Section 16(a) Reports Householding of Proxy Materials Where You Can Find More Information App endix A MacroG enics , Inc. 2023 Equity Incentive Plan , As Amended MacroGenics, Inc. 9704 Medical Center Drive Rockville, Maryland 20850 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD May 21, 2024 We have made available to you this proxy statement and the accompanying proxy card because the Board of Directors (the "Board") of MacroGenics, Inc. (referred to herein as the "Company", "MacroGenics", "we", "us" or "our") is soliciting your proxy to vote at our 2024 Annual Meeting of Stockholders (the "Annual Meeting") to be held by means of a virtual format on Tuesday, May 21, 2024, at 900 a.m. Eastern time. Only stockholders of record and beneficial owners of shares of our common stock as of the close of business on March 22, 2024 (the "Record Date"), may attend and participate in the Annual Meeting, including voting and asking questions during the virtual Annual Meeting. You will not be able to attend the Annual Meeting physically in person. In order to attend the Annual Meeting, you must register at www.proxydocs.comMGNX. Upon completing your registration, you will receive further instructions via email, including a unique link that will allow you access to the Annual Meeting and to vote and submit questions during the Annual Meeting. As part of the registration process, you must enter the control number located on your proxy card, voting instruction form, or Notice of Internet Availability (the "Notice"). If, on the Record Date, you are a beneficial owner of shares held in an account at a brokerage firm, bank, dealer or other similar organization, then you are the beneficial owner of shares held in "street name" and you will also need to provide the registered name on your account and the name of your broker, bank or other nominee as part of the registration pro